Welcome to our dedicated page for Cosciens Biopharma news (Ticker: CSCI), a resource for investors and traders seeking the latest updates and insights on Cosciens Biopharma stock.
Cosciens Biopharma (CSCI) provides investors and industry professionals with centralized access to its latest corporate developments through this official news hub. Our repository features verified press releases and regulatory filings, offering transparent insights into the company's progress across therapeutic research, diagnostic innovations, and cosmetic ingredient technologies.
Discover updates spanning clinical trial milestones, strategic partnerships, and regulatory submissions, alongside financial disclosures and manufacturing advancements. All content is sourced directly from CSCI's communications team to ensure accuracy and timeliness.
Key categories include announcements about proprietary extraction technology applications, R&D breakthroughs in disease detection systems, and commercial expansions within the biopharmaceutical sector. This resource eliminates the need to track multiple channels by aggregating essential updates in one professionally curated location.
Bookmark this page for streamlined monitoring of CSCI's operational developments and scientific achievements. For comprehensive understanding of the company's strategic direction, combine these updates with periodic review of official SEC filings and annual reports.
COSCIENS Biopharma (NASDAQ/TSX: CSCI), a life sciences company focused on cosmeceutical, nutraceutical and pharmaceutical products, has received a letter from Goodwood Fund and Puccetti Funds Management proposing six director nominations for the upcoming Annual and Special Meeting of Shareholders. Board Chair Ronnie Miller acknowledged receipt of the nominations and stated that the board will review the contents and determine next steps while maintaining commitment to shareholder interests.
COSCIENS Biopharma (NASDAQ: CSCI) has appointed Anna Biehn as Chief Executive Officer, effective May 5, 2025. Biehn brings over 25 years of experience in consumer products and biosciences industries, most recently serving as CFO of NuTek Natural Ingredients.
Current President and CEO Gilles Gagnon, who has been with the company since 2008, will transition to a Strategic Advisor and Director role. The leadership change comes as COSCIENS, a life science company developing cosmeceutical, nutraceutical and pharmaceutical products, aims to strengthen its position in natural-based products for health and wellness.
Biehn's previous experience includes serving as VP Strategy and Marketing at NuTek Natural Ingredients and President of Consumer Foods International at Conagra. She holds board positions at PretzelHaus Bakery and Baldwin Richardson Foods, and has an MBA from the University of Denver.
COSCIENS Biopharma (NASDAQ: CSCI) has reported its Q4 and full-year 2024 financial results, marking a transformative year with a strategic repositioning as a pure-play natural-based product company. The company achieved revenues of $9.6M in 2024, up 35.2% from $7.1M in 2023.
Key financial highlights include a cash position of $16.4M as of December 31, 2024, and a full-year net loss of $15.3M ($5.93 per share) compared to $3.5M loss in 2023. Operating expenses increased to $23.0M from $7.5M in 2023.
Development updates include successful Phase 1 results for Avenanthramides Tablets, launch of Phase 2a clinical study, and progress in cosmeceuticals and nutraceuticals. The company has halted investment in pre-clinical programs and macimorelin development following negative Phase 3 DETECT-Trial results. New product launches planned include OBG chewable bars and YBG immune booster products in H2 2025.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) has received a Management Cease Trade Order (MCTO) from the Ontario Securities Commission effective April 1, 2025. The MCTO was issued due to potential delays in filing required annual financial documents for 2022-2024, including financial statements, management discussion, CEO/CFO certificates, and Form 20-F.
The company expects to complete these filings by April 7, 2025. The MCTO restricts the CEO and CFO from trading company securities until the required filings are completed. Regular shareholders unaffected by this order can continue trading normally.
While the MCTO won't immediately impact CSCI's Nasdaq Capital Market listing, the company must issue bi-weekly status updates until the situation is resolved. COSCIENS confirms no material changes since their March 19 default announcement.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced potential delays in filing its annual financial statements, CEO/CFO certificates, and annual information form (Form 20-F) beyond the March 31, 2025 deadline. The delay stems from complications following the 2024 all-stock merger with Ceapro, requiring additional time for accounting procedure conversion and internal control review.
The company identified material weaknesses in financial controls as of December 31, 2024, with deficiencies in the COSO framework principles. Additional review is also needed regarding the impact of prospective U.S. tariffs.
As a precautionary measure, COSCIENS has applied for a management cease trade order (MCTO) with the Ontario Securities Commission. The company confirms this potential delay does not immediately affect its Nasdaq Capital Market listing and will issue bi-weekly status updates if an MCTO is granted.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced potential delays in filing its annual financial statements, CEO/CFO certificates, and annual information form (Form 20-F) beyond the March 31, 2025 deadline. The delay stems from complications related to their 2024 all-stock merger with Ceapro, requiring accounting procedure conversions to meet SEC reporting obligations.
The company identified material weaknesses in financial controls as of December 31, 2024, with deficiencies in the COSO framework principles. Additional review is also needed regarding the impact of prospective U.S. tariffs. As a precautionary measure, COSCIENS has applied for a management cease trade order (MCTO) with the Ontario Securities Commission, though this won't affect non-management trading.
While the delay doesn't immediately impact CSCI's Nasdaq Capital Market listing, the company commits to issuing bi-weekly status updates and completing the required filings as soon as possible.
COSCIENS Biopharma (NASDAQ: CSCI) has announced successful Phase 1 results for its avenanthramides product, leading to the initiation of a Phase 2a clinical efficacy trial. The study, known as AvenActive, demonstrated no significant adverse events in Phase 1, which included 72 healthy subjects receiving doses from 30mg to 960mg per day.
The Phase 2a portion will evaluate 20 patients with mild to moderate inflammation, testing doses of 480mg and 960mg daily. The first patient treatment is scheduled for March 14, 2025, at the Montreal Heart Institute. Avenanthramides, di-phenolic compounds found exclusively in oats, have shown potential antioxidant and anti-inflammatory effects in previous studies.
The trial will assess inflammatory biomarkers in blood, including cytokines, chemokines, and high-sensitivity C-reactive protein. The company aims to pursue out-licensing opportunities and potential commercialization with a major pharmaceutical partner following the completion of Phase 2a.
COSCIENS Biopharma (NASDAQ/TSX: CSCI) provided a corporate update focusing on pipeline prioritization and strategic developments. The company is streamlining operations to focus on natural-based products across cosmeceuticals, nutraceuticals, and pharmaceuticals. Key developments include:
- Phase 1 completion of Avenanthramides Tablets clinical trial with Phase 2a expected in Q1 2025
- Successful production of Enriched Oat Flour
- Launch of JuventeDC website
- Development of Yeast Beta Glucan immune booster for Q2 2025 launch
- Planned Q1 2025 launch of Oat Beta Glucan chewable bar
The company announced the failure of macimorelin DETECT-trial for CGHD diagnosis and will discontinue its development while maintaining its AGHD indication. Cost-cutting measures include management restructuring, with CMO Dr. Nicola Ammer departing in March 2025.
FAQ
What is the current stock price of Cosciens Biopharma (CSCI)?
What is the market cap of Cosciens Biopharma (CSCI)?
